Your browser doesn't support javascript.
loading
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Brastianos, Priscilla K; Lee, Eudocia Quant; Cohen, Justine V; Tolaney, Sara M; Lin, Nancy U; Wang, Nancy; Chukwueke, Ugonma; White, Michael D; Nayyar, Naema; Kim, Albert; Alvarez-Breckenridge, Christopher; Krop, Ian; Mahar, Maura Keeley; Bertalan, Mia S; Shaw, Brian; Mora, Joana L; Goss, Nathaniel; Subramanian, Megha; Nayak, Lakshmi; Dietrich, Jorg; Forst, Deborah A; Nahed, Brian V; Batchelor, Tracy T; Shih, Helen A; Gerstner, Elizabeth R; Moy, Beverly; Lawrence, Donald; Giobbie-Hurder, Anita; Carter, Scott L; Oh, Kevin; Cahill, Daniel P; Sullivan, Ryan J.
Afiliação
  • Brastianos PK; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu.
  • Lee EQ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Cohen JV; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lin NU; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Wang N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Chukwueke U; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • White MD; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Nayyar N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Kim A; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Alvarez-Breckenridge C; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Krop I; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Mahar MK; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Bertalan MS; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Shaw B; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Mora JL; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Goss N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Subramanian M; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Nayak L; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Dietrich J; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Forst DA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Nahed BV; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Batchelor TT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Shih HA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Gerstner ER; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Moy B; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Lawrence D; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Giobbie-Hurder A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Carter SL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Oh K; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Cahill DP; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nat Med ; 26(8): 1309, 2020 Aug.
Article em En | MEDLINE | ID: mdl-32555425
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article